{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T19:00:47Z","timestamp":1792868447383,"version":"4.5.0"},"reference-count":129,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T00:00:00Z","timestamp":1505952000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T00:00:00Z","timestamp":1505952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Cancer Care"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1111\/ecc.12761","type":"journal-article","created":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T08:42:45Z","timestamp":1505983365000},"page":"e12761","source":"Crossref","is-referenced-by-count":47,"title":["Mechanisms of bone destruction in multiple myeloma"],"prefix":"10.1155","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"E.","family":"Terpos","sequence":"first","affiliation":[{"name":"Department of Clinical Therapeutics; National and Kapodistrian University of Athens School of Medicine; Alexandra General Hospital; Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Christoulas","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics; National and Kapodistrian University of Athens School of Medicine; Alexandra General Hospital; Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gavriatopoulou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics; National and Kapodistrian University of Athens School of Medicine; Alexandra General Hospital; Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics; National and Kapodistrian University of Athens School of Medicine; Alexandra General Hospital; Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,9,21]]},"reference":[{"key":"10.1111\/ecc.12761-BIB0001|ecc12761-cit-0001","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.12835","article-title":"Sotatercept in patients with osteolytic lesions of multiple myeloma","volume":"165","author":"Abdulkadyrov","year":"2014","journal-title":"British Journal of Haematology"},{"key":"10.1111\/ecc.12761-BIB0002|ecc12761-cit-0002","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","article-title":"Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma","volume":"100","author":"Abe","year":"2002","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0003|ecc12761-cit-0003","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2003-11-3839","article-title":"Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: A vicious cycle between bone destruction and myeloma expansion","volume":"104","author":"Abe","year":"2004","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0004|ecc12761-cit-0004","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1158\/1541-7786.MCR-16-0242-T","article-title":"EZH2 or HDAC1 inhibition reverses\u00a0multiple myeloma-induced epigenetic suppression of osteoblast differentiation","volume":"15","author":"Adamik","year":"2017","journal-title":"Molecular Cancer Research"},{"key":"10.1111\/ecc.12761-BIB0005|ecc12761-cit-0005","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1083\/jcb.201207142","article-title":"Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin","volume":"200","author":"Albers","year":"2013","journal-title":"The Journal of Cell Biology"},{"key":"10.1111\/ecc.12761-BIB0006|ecc12761-cit-0006","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood-2006-07-035857","article-title":"Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma","volume":"109","author":"Alsayed","year":"2007","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0007|ecc12761-cit-0007","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/jcb.21553","article-title":"The osteoclast: A multinucleated, hematopoietic-origin, bone-resorbing osteoimmune cell","volume":"102","author":"Bar-Shavit","year":"2007","journal-title":"Journal of Cellular Biochemistry"},{"key":"10.1111\/ecc.12761-BIB0008|ecc12761-cit-0008","doi-asserted-by":"crossref","first-page":"e57393","DOI":"10.1371\/journal.pone.0057393","article-title":"Down-regulation of canonical and up-regulation of non-canonical Wnt signalling in the carcinogenic process of squamous cell lung carcinoma","volume":"8","author":"Bartis","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1111\/ecc.12761-BIB0009|ecc12761-cit-0009","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI115305","article-title":"Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma","volume":"88","author":"Bataille","year":"1991","journal-title":"Journal of Clinical Investigation"},{"key":"10.1111\/ecc.12761-BIB0010|ecc12761-cit-0010","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.exphem.2010.11.010","article-title":"CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth","volume":"39","author":"Beider","year":"2011","journal-title":"Experimental Hematology"},{"key":"10.1111\/ecc.12761-BIB0011|ecc12761-cit-0011","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00223-013-9774-y","article-title":"Osteocyte-driven bone remodeling","volume":"94","author":"Bellido","year":"2013","journal-title":"Calcified Tissue International"},{"key":"10.1111\/ecc.12761-BIB0012|ecc12761-cit-0012","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jbmr.320","article-title":"The amazing osteocyte","volume":"26","author":"Bonewald","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1111\/ecc.12761-BIB0013|ecc12761-cit-0013","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1182\/blood.V88.10.3998.bloodjournal88103998","article-title":"Hepatocyte growth factor and its receptor c-met in multiple myeloma","volume":"88","author":"Borset","year":"1996","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0014|ecc12761-cit-0014","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa013444","article-title":"High bone density due to a mutation in LDL receptor- related protein 5","volume":"346","author":"Boyden","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/ecc.12761-BIB0015|ecc12761-cit-0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"10.1111\/ecc.12761-BIB0016|ecc12761-cit-0016","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1046\/j.1365-2141.1999.01194.x","article-title":"Economic impact of using clodronate in the management of patients with multiple myeloma","volume":"104","author":"Bruce","year":"1999","journal-title":"British Journal of Haematology"},{"key":"10.1111\/ecc.12761-BIB0017|ecc12761-cit-0017","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes & Development"},{"key":"10.1111\/ecc.12761-BIB0018|ecc12761-cit-0018","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood.V96.2.671","article-title":"Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma","volume":"96","author":"Choi","year":"2000","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0019|ecc12761-cit-0019","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1172\/JCI200113116","article-title":"Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease","volume":"108","author":"Choi","year":"2001","journal-title":"Journal of Clinical Investigation"},{"key":"10.1111\/ecc.12761-BIB0020|ecc12761-cit-0020","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1586\/ehm.09.36","article-title":"Pathogenesis and management of myeloma bone disease","volume":"2","author":"Christoulas","year":"2009","journal-title":"Expert Review of Hematology"},{"key":"10.1111\/ecc.12761-BIB0021|ecc12761-cit-0021","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"European Journal of Cancer"},{"key":"10.1111\/ecc.12761-BIB0022|ecc12761-cit-0022","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1038\/bcj.2011.22","article-title":"Myeloma cells suppress osteoblasts through sclerostin secretion","volume":"1","author":"Colucci","year":"2011","journal-title":"Blood Cancer Journal"},{"key":"10.1111\/ecc.12761-BIB0023|ecc12761-cit-0023","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","article-title":"Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma","volume":"98","author":"Croucher","year":"2001","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0024|ecc12761-cit-0024","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood.V95.8.2630","article-title":"Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma","volume":"95","author":"Dankbar","year":"2000","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0025|ecc12761-cit-0025","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1172\/JCI117990","article-title":"Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo","volume":"95","author":"Mata","year":"1995","journal-title":"Journal of Clinical Investigation"},{"key":"10.1111\/ecc.12761-BIB0026|ecc12761-cit-0026","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2017.152","article-title":"Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth","author":"Delgado-Calle","year":"2017","journal-title":"Leukemia"},{"key":"10.1111\/ecc.12761-BIB0027|ecc12761-cit-0027","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1182\/blood.V122.21.3140.3140","article-title":"Direct cell-to-cell interactions between osteocytes and multiple myeloma [MM] cells upregulate Sost and downregulate OPG expression in osteocytes: Evidence for osteocytic contributions to MM-induced bone disease","volume":"122","author":"Delgado-Calle","year":"2013","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0028|ecc12761-cit-0028","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes & Development"},{"key":"10.1111\/ecc.12761-BIB0029|ecc12761-cit-0029","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1182\/blood-2011-04-346775","article-title":"Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease","volume":"118","author":"D'Souza","year":"2011","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0030|ecc12761-cit-0030","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2005-03-1080","article-title":"IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma","volume":"106","author":"Ehrlich","year":"2005","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0031|ecc12761-cit-0031","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1096\/fj.07-8080com","article-title":"The activin A-follistatin system: Potent regulator of human extracellular matrix mineralization","volume":"21","author":"Eijken","year":"2007","journal-title":"The FASEB Journal"},{"key":"10.1111\/ecc.12761-BIB0032|ecc12761-cit-0032","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF00163574","article-title":"Myeloma affects both the growth and function of human osteoblast-like cells","volume":"10","author":"Evans","year":"1992","journal-title":"Clinical and Experimental Metastasis"},{"key":"10.1111\/ecc.12761-BIB0033|ecc12761-cit-0033","first-page":"5438","article-title":"Receptor activator of nuclear factor-kappa B ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo","volume":"63","author":"Farrugia","year":"2003","journal-title":"Cancer Research"},{"key":"10.1111\/ecc.12761-BIB0034|ecc12761-cit-0034","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S8756-3282(99)00275-6","article-title":"Transforming growth factor-beta increases interleukin-6 transcripts in osteoblasts","volume":"26","author":"Franchimont","year":"2000","journal-title":"Bone"},{"key":"10.1111\/ecc.12761-BIB0035|ecc12761-cit-0035","doi-asserted-by":"crossref","first-page":"7144","DOI":"10.1158\/1078-0432.CCR-09-1483","article-title":"A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma","volume":"15","author":"Fulciniti","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"10.1111\/ecc.12761-BIB0036|ecc12761-cit-0036","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1006\/bbrc.2000.2075","article-title":"Activin A is an essential cofactor for osteoclast induction","volume":"268","author":"Fuller","year":"2000","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1111\/ecc.12761-BIB0037|ecc12761-cit-0037","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1517\/14728220903025770","article-title":"Dickkopf-1: A suitable target for the management of myeloma bone disease","volume":"13","author":"Gavriatopoulou","year":"2009","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"10.1111\/ecc.12761-BIB0038|ecc12761-cit-0038","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/bit.20939","article-title":"Differentiation of mesenchymal stem cells into osteoblasts on honeycomb collagen scaffolds","volume":"95","author":"George","year":"2006","journal-title":"Biotechnology and Bioengineering"},{"key":"10.1111\/ecc.12761-BIB0039|ecc12761-cit-0039","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0040|ecc12761-cit-0040","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0041|ecc12761-cit-0041","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1182\/blood-2002-04-1121","article-title":"Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: A potential role in multiple myeloma bone disease","volume":"100","author":"Giuliani","year":"2002","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0042|ecc12761-cit-0042","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/leu.2011.381","article-title":"Increased osteocyte death in multiple myeloma patients: Role in myeloma-induced osteoclast formation","volume":"26","author":"Giuliani","year":"2012","journal-title":"Leukemia"},{"key":"10.1111\/ecc.12761-BIB0043|ecc12761-cit-0043","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","article-title":"Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition","volume":"108","author":"Giuliani","year":"2006","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0044|ecc12761-cit-0044","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","article-title":"Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation","volume":"8","author":"Glass","year":"2005","journal-title":"Developmental Cell"},{"key":"10.1111\/ecc.12761-BIB0045|ecc12761-cit-0045","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","article-title":"LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development","volume":"107","author":"Gong","year":"2001","journal-title":"Cell"},{"key":"10.1111\/ecc.12761-BIB0046|ecc12761-cit-0046","first-page":"266","article-title":"Osteogenic inhibition in multiple myeloma","volume":"15","author":"Habibi","year":"2013","journal-title":"Cell Journal"},{"key":"10.1111\/ecc.12761-BIB0501|ecc12761-cit-0501","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nri2998","article-title":"Expanding TRAF function: TRAF3 as a tri-faced immune regulator","volume":"11","author":"H\u00e4cker","year":"2011","journal-title":"Nature Reviews Immunology"},{"key":"10.1111\/ecc.12761-BIB0047|ecc12761-cit-0047","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1182\/blood.V97.11.3349","article-title":"Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand","volume":"97","author":"Han","year":"2001","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0048|ecc12761-cit-0048","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1158\/1078-0432.CCR-04-0632","article-title":"Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment","volume":"10","author":"Hayashi","year":"2004","journal-title":"Clinical Cancer Research"},{"key":"10.1111\/ecc.12761-BIB0049|ecc12761-cit-0049","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/B978-0-12-385961-7.00013-5","article-title":"The regulation and functions of activin and follistatin in inflammation and immunity","volume":"85","author":"Hedger","year":"2011","journal-title":"Vitamins and Hormones"},{"key":"10.1111\/ecc.12761-BIB0050|ecc12761-cit-0050","first-page":"1436","article-title":"Expression of receptor activator of nuclear factor kappa B ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma","volume":"9","author":"Heider","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"10.1111\/ecc.12761-BIB0051|ecc12761-cit-0051","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1530\/eje.0.1390152","article-title":"Osteoprotegerin and its cognate ligand: A new paradigm of osteoclastogenesis","volume":"139","author":"Hofbauer","year":"1998","journal-title":"European Journal of Endocrinology"},{"key":"10.1111\/ecc.12761-BIB0052|ecc12761-cit-0052","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1359\/jbmr.2000.15.1.2","article-title":"The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption","volume":"15","author":"Hofbauer","year":"2000","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1111\/ecc.12761-BIB0053|ecc12761-cit-0053","first-page":"1","article-title":"Light and electron microscopic structure of bone forming cells. The osteocyte","volume":"1","author":"Holtrop","year":"1990","journal-title":"Bone"},{"key":"10.1111\/ecc.12761-BIB0054|ecc12761-cit-0054","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1073\/pnas.96.7.3540","article-title":"Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand","volume":"96","author":"Hsu","year":"1999","journal-title":"Proceedings of the National Academy of Sciences USA"},{"key":"10.1111\/ecc.12761-BIB0055|ecc12761-cit-0055","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.13056","article-title":"A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory\u00a0multiple myeloma\u00a0and prior skeletal-related events","volume":"167","author":"Iyer","year":"2014","journal-title":"British Journal of Haematology"},{"key":"10.1111\/ecc.12761-BIB0056|ecc12761-cit-0056","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/clinchem\/47.1.74","article-title":"Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity","volume":"47","author":"Janckila","year":"2001","journal-title":"Clinical Chemistry"},{"key":"10.1111\/ecc.12761-BIB0502|ecc12761-cit-0502","doi-asserted-by":"crossref","first-page":"37427","DOI":"10.1074\/jbc.M110.149484","article-title":"Receptor activator of NF-{kappa}B (RANK) cytoplasmic IVVY535-538 motif plays an essential role in tumor necrosis factor-{alpha} (TNF)-mediated osteoclastogenesis","volume":"285","author":"Jules","year":"2010","journal-title":"Journal of Biological Chemistry"},{"key":"10.1111\/ecc.12761-BIB0057|ecc12761-cit-0057","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1600-0609.2008.01065.x","article-title":"Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma","volume":"80","author":"Kaiser","year":"2008","journal-title":"European Journal of Haematology"},{"key":"10.1111\/ecc.12761-BIB0058|ecc12761-cit-0058","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1365-2141.2000.01845.x","article-title":"Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts","volume":"108","author":"Karadag","year":"2000","journal-title":"British Journal of Haematology"},{"key":"10.1111\/ecc.12761-BIB0059|ecc12761-cit-0059","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.lfs.2007.04.011","article-title":"Changes in extracellular activin A:Follistatin ratio during differentiation of a mesenchymal progenitor cell line, ROB-C26 into osteoblasts and adipocytes","volume":"81","author":"Kawabata","year":"2007","journal-title":"Life Sciences"},{"key":"10.1111\/ecc.12761-BIB0060|ecc12761-cit-0060","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1242\/jcs.00623","article-title":"Secreted antagonists of the Wnt signalling pathway","volume":"116","author":"Kawano","year":"2003","journal-title":"Journal of Cell Science"},{"key":"10.1111\/ecc.12761-BIB0061|ecc12761-cit-0061","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1111\/ecc.12761-BIB0062|ecc12761-cit-0062","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1111\/ecc.12761-BIB0063|ecc12761-cit-0063","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1046\/j.1365-2141.1996.d01-1491.x","article-title":"Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma (MM)","volume":"92","author":"Kyrstsonis","year":"1996","journal-title":"British Journal of Haematology"},{"key":"10.1111\/ecc.12761-BIB0064|ecc12761-cit-0064","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1111\/ecc.12761-BIB0065|ecc12761-cit-0065","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","article-title":"IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells","volume":"103","author":"Lee","year":"2004","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0066|ecc12761-cit-0066","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1182\/blood-2002-08-2383","article-title":"Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells","volume":"101","author":"Lentzsch","year":"2003","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0067|ecc12761-cit-0067","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ajpath.2015.11.003","article-title":"Inhibition of transforming growth factor-beta activation diminishes tumor progression and osteolytic bone disease in mouse models of multiple myeloma","volume":"186","author":"Lu","year":"2016","journal-title":"The American Journal of Pathology"},{"key":"10.1111\/ecc.12761-BIB0068|ecc12761-cit-0068","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1530\/eje.0.1450225","article-title":"Expression and secretion of activin A: Possible physiological and clinical implications","volume":"145","author":"Luisi","year":"2001","journal-title":"European Journal of Endocrinology"},{"key":"10.1111\/ecc.12761-BIB0069|ecc12761-cit-0069","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1182\/blood-2002-11-3385","article-title":"Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease","volume":"101","author":"Magrangeas","year":"2003","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0070|ecc12761-cit-0070","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/ecc.12761-BIB0071|ecc12761-cit-0071","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood-2017-03-773341","article-title":"Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma","volume":"129","author":"McDonald","year":"2017","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0072|ecc12761-cit-0072","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1210\/endo-119-4-1654","article-title":"Osteoblast-like cells in the presence of parathyroid hormone release soluble factor that stimulates osteoclastic bone resorption","volume":"119","author":"McSheehy","year":"1986","journal-title":"Endocrinology"},{"key":"10.1111\/ecc.12761-BIB0073|ecc12761-cit-0073","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.ejca.2005.12.025","article-title":"The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions","volume":"42","author":"Mitsiades","year":"2006","journal-title":"European Journal of Cancer"},{"key":"10.1111\/ecc.12761-BIB0074|ecc12761-cit-0074","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1006\/bbrc.1998.8697","article-title":"Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor\/osteoprotegerin","volume":"247","author":"Mizuno","year":"1998","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1111\/ecc.12761-BIB0075|ecc12761-cit-0075","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00223-010-9372-1","article-title":"Sclerostin: Current knowledge and future perspectives","volume":"87","author":"Moester","year":"2010","journal-title":"Calcified Tissue International"},{"key":"10.1111\/ecc.12761-BIB0076|ecc12761-cit-0076","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/cncr.28481","article-title":"The effects of bortezomib on bone disease in patients with multiple myeloma","volume":"120","author":"Mohty","year":"2014","journal-title":"Cancer"},{"key":"10.1111\/ecc.12761-BIB0077|ecc12761-cit-0077","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/bbrc.1998.9788","article-title":"RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis","volume":"253","author":"Nakagawa","year":"1998","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1111\/ecc.12761-BIB0078|ecc12761-cit-0078","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/09243860500096248","article-title":"Microdamage and apoptosis","volume":"42","author":"Noble","year":"2005","journal-title":"European Journal of Morphology"},{"key":"10.1111\/ecc.12761-BIB0079|ecc12761-cit-0079","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood-2004-12-4940","article-title":"Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2","volume":"106","author":"Oshima","year":"2005","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0080|ecc12761-cit-0080","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1210\/endo-128-3-1496","article-title":"Pleiotropic effects of vitamin D on osteoblast gene expression are related to the proliferative and differentiated state of the bone cell phenotype: Dependency upon basal levels of gene expression, duration of exposure, and bone matrix competency in normal rat osteoblast cultures","volume":"128","author":"Owen","year":"1991","journal-title":"Endocrinology"},{"key":"10.1111\/ecc.12761-BIB0081|ecc12761-cit-0081","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","article-title":"Dual effects of macrophage inflammatory protein-1 alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease","volume":"102","author":"Oyajobi","year":"2003","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0082|ecc12761-cit-0082","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"Proceedings of the National Academy of Sciences USA"},{"key":"10.1111\/ecc.12761-BIB0083|ecc12761-cit-0083","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/ortho\/25.2.101","article-title":"Bone remodelling","volume":"25","author":"Phill","year":"1998","journal-title":"British Journal of Orthodontics"},{"key":"10.1111\/ecc.12761-BIB0084|ecc12761-cit-0084","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11914-014-0194-3","article-title":"Apoptotic osteocytes and the control of targeted bone resorption","volume":"12","author":"Plotkin","year":"2014","journal-title":"Current Osteoporosis Reports"},{"key":"10.1111\/ecc.12761-BIB0085|ecc12761-cit-0085","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/ijc.22033","article-title":"Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation","volume":"119","author":"Politou","year":"2006","journal-title":"International Journal of Cancer"},{"key":"10.1111\/ecc.12761-BIB0086|ecc12761-cit-0086","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2004.05092.x","article-title":"Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)","volume":"126","author":"Politou","year":"2004","journal-title":"British Journal of Haematology"},{"key":"10.1111\/ecc.12761-BIB0087|ecc12761-cit-0087","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/ncb2976","article-title":"Oncogenic roles of EMT-inducing transcription factors","volume":"16","author":"Puisieux","year":"2014","journal-title":"Nature Cell Biology"},{"key":"10.1111\/ecc.12761-BIB0088|ecc12761-cit-0088","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1182\/blood-2008-01-132134","article-title":"Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: A potential mechanism underlying osteolytic bone lesions in multiple myeloma","volume":"112","author":"Qiang","year":"2008","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0089|ecc12761-cit-0089","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.bcmd.2004.01.001","article-title":"Pathogenesis of myeloma bone disease","volume":"32","author":"Roodman","year":"2004","journal-title":"Blood Cells, Molecules, and Diseases"},{"key":"10.1111\/ecc.12761-BIB0090|ecc12761-cit-0090","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"10.1111\/ecc.12761-BIB0091|ecc12761-cit-0091","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1046\/j.1365-2141.1998.00687.x","article-title":"Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"101","author":"Sati","year":"1998","journal-title":"British Journal of Haematology"},{"key":"10.1111\/ecc.12761-BIB0092|ecc12761-cit-0092","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1046\/j.1365-2141.1999.01193.x","article-title":"Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma","volume":"104","author":"Sati","year":"1999","journal-title":"British Journal of Haematology"},{"key":"10.1111\/ecc.12761-BIB0093|ecc12761-cit-0093","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1046\/j.1365-2141.2002.03898.x","article-title":"Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy","volume":"119","author":"Seidel","year":"2002","journal-title":"British Journal of Haematology"},{"key":"10.1111\/ecc.12761-BIB0094|ecc12761-cit-0094","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1182\/blood-2012-04-417337","article-title":"Metastatic myeloma?","volume":"119","author":"Shain","year":"2012","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0095|ecc12761-cit-0095","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: A novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"10.1111\/ecc.12761-BIB0096|ecc12761-cit-0096","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1242\/jcs.02883","article-title":"Wnt signalling in osteoblasts regulates expression of the receptor activator of NF kappaB ligand and inhibits osteoclastogenesis in vitro","volume":"119","author":"Spencer","year":"2006","journal-title":"Journal of Cell Science"},{"key":"10.1111\/ecc.12761-BIB0097|ecc12761-cit-0097","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2006-07-034884","article-title":"HGF inhibits BMP-induced osteoblastogenesis: Possible implications for the bone disease of multiple myeloma","volume":"109","author":"Standal","year":"2007","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0098|ecc12761-cit-0098","first-page":"174","article-title":"Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma","volume":"89","author":"Standal","year":"2004","journal-title":"Haematologica"},{"key":"10.1111\/ecc.12761-BIB0099|ecc12761-cit-0099","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2002-04-1190","article-title":"Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells","volume":"100","author":"Standal","year":"2002","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0100|ecc12761-cit-0100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/jcb.10613","article-title":"Activin A stimulates IkappaB-alpha\/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors","volume":"90","author":"Sugatani","year":"2003","journal-title":"Journal of Cellular Biochemistry"},{"key":"10.1111\/ecc.12761-BIB0101|ecc12761-cit-0101","doi-asserted-by":"crossref","first-page":"e9870","DOI":"10.1371\/journal.pone.0009870","article-title":"Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth","volume":"5","author":"Takeuchi","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1111\/ecc.12761-BIB0102|ecc12761-cit-0102","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1158\/1078-0432.CCR-06-2258","article-title":"Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: A role for vascular endothelial cell growth factor and osteopontin","volume":"13","author":"Tanaka","year":"2007","journal-title":"Clinical Cancer Research"},{"key":"10.1111\/ecc.12761-BIB0103|ecc12761-cit-0103","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/labinvest.2012.108","article-title":"VEGF, FLT3 ligand, PlGF and HGF can substitute for M-CSF to induce human osteoclast formation: Implications for giant cell tumour pathobiology","volume":"92","author":"Taylor","year":"2012","journal-title":"Laboratory Investigation"},{"key":"10.1111\/ecc.12761-BIB0104|ecc12761-cit-0104","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/17474086.2013.874943","article-title":"Management of bone disease in multiple myeloma","volume":"7","author":"Terpos","year":"2014","journal-title":"Expert Review of Hematology"},{"key":"10.1111\/ecc.12761-BIB0105|ecc12761-cit-0105","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.27342","article-title":"Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy","volume":"131","author":"Terpos","year":"2012","journal-title":"International Journal of Cancer"},{"key":"10.1111\/ecc.12761-BIB0106|ecc12761-cit-0106","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","article-title":"Bortezomib\u00a0reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of\u00a0bone\u00a0remodelling in patients with relapsed\u00a0multiple myeloma","volume":"135","author":"Terpos","year":"2006","journal-title":"British Journal of Haematology"},{"key":"10.1111\/ecc.12761-BIB0107|ecc12761-cit-0107","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/annonc\/mds068","article-title":"Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy","volume":"23","author":"Terpos","year":"2012","journal-title":"Annals of Oncology"},{"key":"10.1111\/ecc.12761-BIB0108|ecc12761-cit-0108","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1365-2141.2003.04561.x","article-title":"Serum levels of macrophage inflammatory protein-1 alpha (MIP-1\u03b1) correlate with the extent of bone disease and survival in patients with Multiple Myeloma","volume":"123","author":"Terpos","year":"2003","journal-title":"British Journal of Haematology"},{"issue":"S2","key":"10.1111\/ecc.12761-BIB0109|ecc12761-cit-0109","first-page":"S782","article-title":"Comparison of denosumab with zoledronic acid for the treatment of bone disease in patients with newly diagnosed Multiple Myeloma; an international, randomized, double blind trial","volume":"102","author":"Terpos","year":"2017","journal-title":"Haematologica"},{"key":"10.1111\/ecc.12761-BIB0110|ecc12761-cit-0110","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligandosteoprotegerin ratio predicts survival in multiple myeloma: Proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0111|ecc12761-cit-0111","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/ecc.12761-BIB0112|ecc12761-cit-0112","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1182\/blood-2003-12-4386","article-title":"Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator","volume":"104","author":"Tjin","year":"2004","journal-title":"Blood"},{"key":"10.1111\/ecc.12761-BIB0113|ecc12761-cit-0113","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/jbmr.2741","article-title":"The proteasome inhibitor bortezomib maintains\u00a0osteocyte\u00a0viability in\u00a0multiple myeloma\u00a0patients by reducing both apoptosis and autophagy: A new function for proteasome inhibitors","volume":"31","author":"Toscani","year":"2016","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1111\/ecc.12761-BIB0114|ecc12761-cit-0114","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1006\/bbrc.1998.8610","article-title":"Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone","volume":"246","author":"Tsukii","year":"1998","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1111\/ecc.12761-BIB0115|ecc12761-cit-0115","doi-asserted-by":"crossref","first-page":"7260","DOI":"10.1073\/pnas.87.18.7260","article-title":"Origin of osteoclasts: Mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells","volume":"87","author":"Udagawa","year":"1990","journal-title":"Proceedings of the National Academy of Sciences USA"},{"key":"10.1111\/ecc.12761-BIB0116|ecc12761-cit-0116","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2141.2003.04040.x","article-title":"Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM","volume":"120","author":"Uneda","year":"2003","journal-title":"British Journal of Haematology"},{"key":"10.1111\/ecc.12761-BIB0117|ecc12761-cit-0117","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.stem.2012.05.023","article-title":"Developmental stage and time dictate the fate of wnt\/beta-catenin-responsive stem cells in the mammary gland","volume":"11","author":"Amerongen","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1111\/ecc.12761-BIB0118|ecc12761-cit-0118","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1046\/j.1365-2141.1998.00835.x","article-title":"Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: A phase I dose-escalating study","volume":"102","author":"Zaanen","year":"1998","journal-title":"British Journal of Haematology"},{"key":"10.1111\/ecc.12761-BIB0119|ecc12761-cit-0119","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bone.2012.12.052","article-title":"Osteoblastic Wnts differentially regulate bone remodeling and the maintenance of bone marrow mesenchymal stem cells","volume":"55","author":"Wan","year":"2013","journal-title":"Bone"},{"key":"10.1111\/ecc.12761-BIB0120|ecc12761-cit-0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.gene.2004.06.044","article-title":"Wnt signaling in osteoblasts and bone diseases","volume":"341","author":"Westendorf","year":"2004","journal-title":"Gene"},{"key":"10.1111\/ecc.12761-BIB0121|ecc12761-cit-0121","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1084\/jem.167.2.570","article-title":"Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties","volume":"167","author":"Wolpe","year":"1988","journal-title":"Journal of Experimental Medicine"},{"key":"10.1111\/ecc.12761-BIB0122|ecc12761-cit-0122","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/jbmr.1547","article-title":"Osteocyte RANKL: New insights into the control of bone remodeling","volume":"27","author":"Xiong","year":"2012","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1111\/ecc.12761-BIB0123|ecc12761-cit-0123","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","article-title":"Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity","volume":"116","author":"Yaccoby","year":"2002","journal-title":"British Journal of Haematology"},{"key":"10.1111\/ecc.12761-BIB0124|ecc12761-cit-0124","first-page":"192","article-title":"Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model","volume":"91","author":"Yaccoby","year":"2006","journal-title":"Haematologica"},{"key":"10.1111\/ecc.12761-BIB0125|ecc12761-cit-0125","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proceedings of the National Academy of Sciences USA"},{"key":"10.1111\/ecc.12761-BIB0126|ecc12761-cit-0126","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/0008-5472.CAN-04-1687","article-title":"Elevated serum levels of stromal-derived factor-1 alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients","volume":"65","author":"Zannettino","year":"2005","journal-title":"Cancer Research"},{"key":"10.1111\/ecc.12761-BIB0127|ecc12761-cit-0127","first-page":"RA175","article-title":"Recent advances in tumor hypoxia: Tumor progression, molecular mechanisms, and therapeutic implications","volume":"13","author":"Zhang","year":"2007","journal-title":"Medical Science Monitor"}],"container-title":["European Journal of Cancer Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fecc.12761","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ecc.12761\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T13:10:44Z","timestamp":1671541844000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ecc.12761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,21]]},"references-count":129,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"URL":"https:\/\/doi.org\/10.1111\/ecc.12761","archive":["Portico"],"relation":{},"ISSN":["0961-5423"],"issn-type":[{"value":"0961-5423","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9,21]]}}}